Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BTK C481F |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BTK C481F | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, the BTK C481F mutation was identified in diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) in culture (PMID: 28178345). | 28178345 | |
| BTK C481F | diffuse large B-cell lymphoma | resistant | Tirabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the BTK C481F mutation, and was resistant to Tirabrutinib (ONO-4059) in culture (PMID: 28178345). | 28178345 | |
| BTK C481F | diffuse large B-cell lymphoma | resistant | Idelalisib | Preclinical - Cell culture | Actionable | In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the BTK C481F mutation, and was resistant to Zydelig (idelalisib) in culture (PMID: 28178345). | 28178345 | |
| BTK C481F | diffuse large B-cell lymphoma | resistant | Idelalisib + Tirabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the BTK C481F mutation, and was resistant to Zydelig (idelalisib) and Tirabrutinib (ONO-4059) combination treatment in culture (PMID: 28178345). | 28178345 | |
| BTK C481F | mantle cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a mantle cell lymphoma cell line developed resistance to Imbruvica (ibrutinib) after prolonged exposure in culture, and was subsequently found to have acquired BTK C481F (PMID: 36661329). | 36661329 | |
| BTK C481F | mantle cell lymphoma | sensitive | ARQ 531 | Preclinical - Cell culture | Actionable | In a preclinical study, ARQ 531 inhibited viability of a mantle cell lymphoma cell line harboring BTK C481F in culture (PMID: 36661329). | 36661329 | |
| BTK C481F | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, diffuse large B-cell lymphoma cell lines expressing BTK C481F demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 36183831). | 36183831 | |
| BTK C481F | hematologic cancer | resistant | Acalabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BTK C481F were resistant to treatment with Calquence (acalabrutinib) in culture (PMID: 35639855). | 35639855 | |
| BTK C481F | hematologic cancer | resistant | Zanubrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BTK C481F were resistant to treatment with Brukinsa (zanubrutinib) in culture (PMID: 35639855). | 35639855 | |
| BTK C481F | lymphoma | predicted - sensitive | DZD8586 | Preclinical - Cell culture | Actionable | In a preclinical study, DZD8586 inhibited proliferation of lymphoma cells expressing BTK C481F in culture (Blood (2023) 142 (Supplement 1): 2822). | detail... | |
| BTK C481F | hematologic cancer | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing BTK C481F were resistant to treatment with Imbruvica (ibrutinib) in culture (PMID: 35639855). | 35639855 |